Logo for Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Investor Relations Material

Latest events

Logo for Ultragenyx Pharmaceutical Inc

AGM 2024

Ultragenyx Pharmaceutical
Logo for Ultragenyx Pharmaceutical

AGM 2024

18 Jun, 2024
Logo for Ultragenyx Pharmaceutical

Q1 2024

2 May, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Ultragenyx Pharmaceutical Inc

Access all reports
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focuses on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe and internationally. It biologic products include Crysvita (burosumab) as an antibody targeting fibroblast growth factor 23 for treatment of X-linked hypophosphatemia; Mepsevii as an enzyme replacement therapy for the treatment of children and adults with mucopolysaccharidosis VII; Dojolvi like evinacumab for treating long-chain fatty acid oxidation disorders; Evkeeza (evinacumab) like ezetimibe for treating homozygous familial hypercholesterolemia.